Veriheal

APRIL 11, 2022

federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

MMJ Recs

NOVEMBER 17, 2023

By legalizing MMJ, the state has facilitated access to a natural and potentially life-changing treatment option for patients suffering from various medical conditions. Support for Patient Well-Being The availability of medical marijuana in local communities fosters an environment of support for patients seeking alternative treatments.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Cannabis Law Report

JUNE 5, 2019

The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths. Effective, most effective in treatment Relieve symptoms.

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40

Veriheal

DECEMBER 28, 2021

Over the last few decades, the cannabis plant and its many components have been the focal point of research and stiff debate. D espite the Drug Enforcement Agency’s (DEA) announcement in May that it would soon start reviewing grower applications for research purposes, cannabis research continues to be tightly restricted.

Research and Development 98

Research and Development Chronic Pain Treatment Medicine 98

Cannabis Law Report

JANUARY 16, 2022

Sativex was developed by GW Pharmaceuticals, a maker of cannabinoid therapeutics based in Ireland. This means Malaysia currently has no registered marijuana-based treatment.

Research and Development 98

Research and Development Pharmaceutical Epilepsy Medicine 98

The Cannigma

JUNE 15, 2021

Both THC and CBD were first isolated in a laboratory in the early 1940s by American researcher Roger Adams. It wasn’t until the 1960s, however, that Israeli researcher Raphael Mechoulam properly identified the chemical structure of CBD, which led to the wealth of knowledge and scope of research we have today. Shutterstock).

CBD 122

CBD Research and Development Epilepsy Extraction 122

The Joint Blog

JULY 17, 2020

According to a new study published in the journal Seminars in Pediatric Neurology, marijuana-based products are associated with improvements in the symptoms of autistic patients who have self-injurious behaviors and co-morbid epilepsy. Those diagnosed with both ASD and epilepsy saw a 91% seizure control improvement.

Epilepsy 47

Epilepsy Research and Development Marijuana Treatment 47

Greencamp

AUGUST 16, 2018

In this comprehensive guide, we are exploring the research on using cannabis for treating Amyotrophic lateral sclerosis (ALS)—a rare neuron disease that targets the motor neurons in the body. Exploring the available research on ALS and cannabinoids. Marijuana and Epilepsy: Here’s How Cannabis Stops Seizures (12 Studies).

Strains 94

Strains Cannabinoids Research and Development Indica 94

The Joint Blog

JANUARY 12, 2020

However, researchers warn that not only are not all CBD pet products made equally, but some contain no CBD at all. You’d be astounded by the analysis we’ve seen of products on the shelf with virtually no CBD in them,” said Cornell University veterinary researcher Joseph Wakshlag: He studies therapeutic uses for the compound.

Pets 36

Pets CBD Clinical Trials Research and Development 36

CannaMD

AUGUST 19, 2020

Researchers with Microbiology and Molecular Biology Reviews elaborate: The term “cytokine storm” calls up vivid images of an immune system gone awry and an inflammatory response flaring out of control. ” And their alternative strategy of choice? SARS-CoV2 is the virus that causes COVID-19.). Terpenes and CBD: Twice as Effective.

Research and Development 141

Research and Development Marijuana Extraction Terpenes 141

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. Adverse mental events were reported as well, however, more research should be performed to assess well this outcome. Scientific Reports volume 11 , Article number: 23462 ( 2021 ) Cite this article.

Safety 52

Safety Cannabinoids Events Data 52

The Cannigma

MARCH 14, 2023

Cancer, HIV, epilepsy and other serious conditions were the first accepted uses of cannabis in the United States. Laws restricting birth control, abortion, drug use, as well as requirements to receive welfare, drug treatment and even pain medication are developed in a paternalistic nature. This is indeed what we found.

Policy 96

Policy Research and Development Conditions Consumption 96

Cannabis Law Report

JULY 25, 2022

To become a registered patient with legal rights to purchase medical marijuana, a state-licensed physician must determine that you would indeed benefit from this treatment. Some of the conditions that qualify for receiving medical marijuana treatment in Pennsylvania include, but are not limited to: Muscle spasticity. Anxiety disorders.

Legalization 52

Legalization Marijuana Epilepsy Sativa 52

Cannabis Law Report

APRIL 4, 2019

House of Hemp hope to build on existing medical research and further explore the potential of cannabis as a healing plant. A big part of the licensing process will be that it will enable cannabis researchers to take their work further and conclusively prove what medical benefits, if any, the plant yields.

Cultivation 40

Cultivation Research and Development Chronic Pain Data 40

Veriheal

AUGUST 31, 2020

We are humbled to introduce you to them and their exceptional ideas, ranging from community grassroots mental health efforts designed to empower historically vulnerable communities of color, to research plans for identifying strain specific genetics. Veriheal’s Innovation in Cannabis Scholarship 2020 Winners . Nishtha Tripathi.

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. What about other medical cannabis products?

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

JANUARY 10, 2022

This high share is attributable to the rising adoption of THCV for various applications such as epilepsy, arthritis, metabolic disorders, neurological disorders, and pain management. Research Methodology. Research Scope And Assumptions. List To Data Sources. For instance, as of June 2021, InMed Pharmaceuticals, Inc.,

Cannabinoids 52

Cannabinoids Clinical Trials Research and Development Supply Chain 52

The Joint Blog

DECEMBER 9, 2019

The twice-daily administration of plant-derived CBD-dominant extracts is associated with symptom improvement in adolescents with autism spectrum disorder (ASD), according to observational data published in the journal Frontiers in Neurology. Due to adverse effects, three patients discontinued CE use before 1 month.

CBD 49

CBD Extraction Epilepsy Sativa 49

Veriheal

MAY 31, 2022

According to data released by the Centers for Disease Control and Prevention , there were an estimated 2,620 opioid overdose deaths in Texas between Aug. Research published in 2016 revealed that 59% of a sample of patients who misused opioids were first exposed to them through a medical prescription.

Programs 52

Programs Chronic Pain Treatment Conditions 52

WeedAdvisor

APRIL 8, 2019

Research is being done into several claims about CBD, specifically anxiety, depression and pain relief. The only actual confirmed benefit of CBD is its effect on Lennox Gastaut Syndrome and Dravet Syndrome – two severe types of epilepsy that do not typically respond to conventional treatment. Confirmed Benefits. . The post U.S.

Food 40

Food CBD Research and Development Treatment 40

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “To BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. About MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

SEPTEMBER 13, 2021

Positive data from this important study would significantly advance MYMD-1’s potential to become a blockbuster drug for inflammation and aging.”. Because it can cross the blood-brain barrier, MYMD-1 is also positioned to be a possible treatment for multiple sclerosis and other brain-related disorders. Chief Scientific Officer.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Cannabis Law Report

JUNE 1, 2021

Drake is well-known as an inspiring and inclusive leader who is dedicated to the development of her teams and solely focused on organizational success for the benefit of patients. Company remains on track for potential approval of Vicineum™ in the US in August 2021. CAMBRIDGE, Mass.–(BUSINESS

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Commence clinical program in PTSD.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

DECEMBER 9, 2019

Although research on CBD is still in its infancy, to date there have been dozens of studies with more on the horizon. Why so little research? Up until December of 2015, regulatory limitations put in place by the FDA prohibited researchers from conducting CBD-related trials in the US. Anxiety and Inflammation Lead the Pack.

Pets 59

Pets CBD Research and Development Epilepsy 59

Greenspoon Marder Cannabis Law Group Blog

APRIL 2, 2019

For example, we’re seeking comments, data and information on a variety of topics including: what levels of cannabis and cannabis-derived compounds cause safety concerns; how the mode of delivery (e.g., For Alzheimer’s patients, CBD is one treatment option that is slowing the progression of that disease.”.

CBD 40

CBD Research and Development Safety Therapy 40

Cannabis Law Report

OCTOBER 26, 2021

MyMD’s lead drug candidate, MYMD-1, is being developed to target aging and related diseases along with autoimmune diseases including rheumatoid arthritis. MyMD’s lead drug candidate, MYMD-1, is being developed to target aging, aging-related diseases, and autoimmune diseases including rheumatoid arthritis. About MYMD-1.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

CannaTech

OCTOBER 14, 2018

Similar conditions in the Imperial Valley of extreme southern California have permitted cultivators like Farmtiva to thrive as the company operates an industrial hemp research and grow facility on 160 acres of a former U.S. Department of Agriculture (USDA) research facility which includes greenhouses and a soil testing laboratory.

Hemp 53

Hemp Research and Development Agriculture Seed-To-Sale 53

Cannabis Info

MARCH 12, 2019

There is no data recorded on any federal database anywhere. As a result, workers who do not protect their skin (and in some cases respiratory passages) when closely working with the plant do seem to develop negative physical reactions. Unfortunately, given the lack of research, not much more is known. This is the one exception.

Research and Development 45

Research and Development Concentrates Cannabinoids Cannabis 45

Cannabis Law Report

JANUARY 20, 2022

Eleusis pioneers the development of psychedelic drug candidates in the life sciences space, with the goal of transforming psychedelics into broadly accessible medicines. Eleusis designed ELE-Psilo, a proprietary psilocybin-based drug candidate that is formulated for IV infusion and in development for the treatment of depression.

Therapy 52

Therapy Research and Development Business Access 52

Cannabis Law Report

NOVEMBER 15, 2021

Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the three and nine months ended September 30, 2021, and other recent developments. “We This product candidate is being funded through a Cooperative Research and Development Agreement (CRADA) with the National Center for Advancing Translational Sciences (NCATS).

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

OCTOBER 6, 2021

Under the terms of this agreement, Sinclair Research will perform preclinical animal studies including method, dosage and toxicity as part of the enabling trials for an Investigational New Drug Application (“IND”) for AnQlar, as required by the U.S. Food and Drug Administration (“FDA”). The studies are expected to begin in January of 2022.

Research and Development 52

Research and Development Clinical Trials Pharmaceutical Chronic Pain 52

The Cannigma

JUNE 29, 2021

Though the distinction between these terms may seem trivial at first glance, it is in fact crucial for cannabis research, and therefore also for consumers and regulators as well. Researchers conducting survey based studies today often only have access to the THC concentration of the cannabis that their participants are using.

Terpenes 138

Terpenes Research and Development Cannabinoids Concentrates 138

Cannabis Law Report

NOVEMBER 24, 2021

Published by The Journal of Cannabis Research. At the same time, the outlook on cannabis research data is largely positive. Primary sources most frequently used in these reports are peer-reviewed journals or government reports, voices from medical associations or foundations, as well as government and university researchers.

Research and Development 52

Research and Development Medicine Access Media 52

WeedAdvisor

APRIL 1, 2019

CBD Oil for dogs, cats and other pets is a natural development of the cannabidiol (CBD) craze. As anecdotal evidence began piling up, some companies decided that CBD’s reported effects on epilepsy (which has been heavily proven), anxiety, insomnia, pain and inflammation – among others – could work on dogs, cats and other pets.

Pets 49

Pets Oil CBD Research and Development 49

CannaTech

SEPTEMBER 23, 2019

This commentary on the NICE UK cannabis guidelines is originally published by The Academy of Medical Cannabis , the globally leading institute for clinical training and research in cannabis-based medicinal products. This bottleneck has left patients and parents to pursue unregulated avenues to access treatment.

Patients 79

Patients Policy Clinical Trials Research and Development 79

Cannabis Law Report

OCTOBER 26, 2019

ii Non-clinical studiesAlthough the use of animals in research is separately regulated by each state and territory, all require compliance with the Australian Code for the Care and Use of Animals for Scientific Purposes (Animal Code). hospital) or a company) and must be approved by a human research ethics committee (HREC).

Clinical Trials 45

Clinical Trials Medicine Research and Development Compliance 45